New drug targets hard-to-treat cancers in small study
NCT ID NCT04504942
First seen Jan 24, 2026 · Last updated May 09, 2026 · Updated 17 times
Summary
This study tested a drug called leronlimab in 16 adults with advanced solid tumors that have a specific protein (CCR5+). The main goals were to check safety and see if the drug could slow tumor growth. Participants had already tried other treatments or had no standard options left.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Quest Clinical Research
San Francisco, California, 94115, United States
Conditions
Explore the condition pages connected to this study.